| Revenue growth | Flat FY27 guidance due to Librela de-stocking headwind. |
|---|---|
| Margins | Mid-20s EBITDA margin targeted through disciplined cost management. |
| Order book | BMS partnership extended to 2035 provides long-term revenue visibility. |
| Demand visibility | Strong pipeline in CDMO biologics and ADC services for FY28. |
| Management confidence | Cautiously optimistic on long-term recovery; defensive regarding near-term flat growth. |
Growth
FY26 revenue grew 3% YoY; Q4 sequential growth of 13% suggests bottoming out despite the Librela impact.
Outlook
Guidance for flat revenue in FY27 with EBITDA margins stabilizing in the mid-20s.
Risks
Heavy client concentration risk with Librela and potential margin pressure from scaling new low-utilization facilities.
Earnings Call filed with NSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹360.15
- Market cap
- ₹14,538 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 65.8×Sector 47.4×
- Promoter holding
- 52.59%-0.09% QoQ
- FII holding
- 11.82%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Management Change
Syngene International Limited announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and Senior Management Personnel, effective September 21, 2026.
Syngene International Other Announcement
Syngene International Limited has issued a communication to shareholders regarding the remittance of the final dividend for the financial year 2025-26.
Syngene International Employee Stock Options
Syngene International has granted 14,26,061 Performance Share Units (PSUs) to eligible employees under the company's 2023 Long Term Incentive Performance Share Plan.
Syngene International Acquisition Worth ₹2.52 Cr
Syngene International Limited is investing ₹2.52 Crore to acquire a 12.44% equity stake in Ampin C&I Power Twelve Private Limited for renewable energy power consumption.
- Value
- ₹2.52 Cr
Syngene International Investor Presentation: Key Takeaways
Syngene reports Q1 FY27 revenue of Rs 736 Cr (-16% YoY). Performance was impacted by low offtake from a major client and forex losses.
Syngene International Annual General Meeting
Syngene International Limited held its 33rd Annual General Meeting on July 29, 2026. The meeting transacted business including the adoption of financial statements and dividend declaration.